Figure 5.

Cell cycle‐related and expression‐elevated protein in tumor (CREPT) overexpression predicts poor prognosis of patients with non‐small‐cell lung cancer. A,B, Patients with lower CREPT expression levels showed better overall survival (P = .01) (A) and better recurrence‐free survival (P = .006) (B). C,D, Kaplan–Meier survival analysis of adenocarcinoma patients (P = .30) (C) and squamous cell carcinoma patients (P = .03) (D), stratified by CREPT expression level. E,F, Kaplan–Meier survival analysis of pTNM I/II patients (P = .588) (E) and pTNM III/IV patients (P = .005) (F), stratified by CREPT expression level. (G,H) Kaplan–Meier survival analysis of lymph node‐negative patients (P = .01) (G) and lymph node‐positive patients (P = .03) (H), stratified by CREPT expression level. I,J, Kaplan–Meier survival analysis of patients with small tumor (diameter ≤5 cm, P = .70) (I) and large tumor (diameter >5 cm, P = .002) (J), stratified by CREPT expression level